Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance

Exclusion criteria

• . Participants who have had chemotherapy based therapy within 12 weeks or Rituximab based therapy within prior 24 weeks prior to starting the cycle 1 Day 1 of trial therapy
• . Participants who are receiving any other investigational agents concurrently.
• . History of severe allergic reactions or anaphylaxis attributed to compounds of similar chemical or biologic composition to Isatuximab.
• . Diagnosis of Multiple Myeloma or High risk smoldering Multiple Myeloma or a B cell lymphoma meeting criteria for therapy.
• . Renal Biopsy showing the coexistence of other significant diagnosis e.g. diabetic nephropathy.
• . Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
• . Pregnant and Lactating women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with Isatuximab.
• . HIV-positive Participants are ineligible because of increased risk of lethal infections when treated with immunosuppressive therapy.